This study is accepting new patients by invitation only

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

a study on Atopic Dermatitis (Eczema)

Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UCLA
Dates
study started
study ends around

Description

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)

Official Title

A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial

Keywords

Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, IMG-007, Dermatitis, Atopic, Dermatitis, Skin Diseases, Immune System Diseases, Dermatologic Agents

Eligibility

For people ages 18-75

Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203

Locations

  • Inmagene Site 23
    Los Angeles California 90095 United States
  • Inmagene Site 1
    Lancaster California 93534 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Inmagene LLC
ID
NCT07734415
Phase
Phase 2 Atopic Dermatitis (Eczema) Research Study
Study Type
Interventional
Participants
Expecting 400 study participants
Last Updated